<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39371431</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2632-8682</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>RSC medicinal chemistry</Title><ISOAbbreviation>RSC Med Chem</ISOAbbreviation></Journal><ArticleTitle>Inhibition of SARS-CoV-2 3CLpro by chemically modified tyrosinase from <i>Agaricus bisporus</i>.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1039/d4md00289j</ELocationID><Abstract><AbstractText>Antiviral compounds are crucial to controlling the SARS-CoV-2 pandemic. Approved drugs have been tested for their efficacy against COVID-19, and new pharmaceuticals are being developed as a complementary tool to vaccines. In this work, a cheap and fast purification method for natural tyrosinase from <i>Agaricus bisporus</i> (AbTyr) fresh mushrooms was developed to evaluate the potential of this enzyme as a therapeutic protein <i>via</i> the inhibition of SARS-CoV-2 3CLpro protease activity <i>in vitro</i>. AbTyr showed a mild inhibition of 3CLpro. Thus, different variants of this protein were synthesized through chemical modifications, covalently binding different tailor-made glycans and peptides to the amino terminal groups of the protein. These new tyrosinase conjugates were purified and characterized through circular dichroism and fluorescence spectroscopy analyses, and their stability was evaluated under different conditions. Subsequently, all these tyrosinase conjugates were tested for 3CLpro protease inhibition. From them, the conjugate between tyrosinase and a dextran-aspartic acid (6 kDa) polymer showed the highest inhibition, with an IC<sub>50</sub> of 2.5 μg ml<sup>-1</sup> and IC<sub>90</sub> of 5 μg ml<sup>-1</sup>, with no cytotoxicity activity by polymer insertion. Finally, SARS-CoV-2 virus infection was studied. It was found that this new AbTyr-Dext6000 protein showed an 80% decrease in viral load. These results show the capacity of these tyrosinase bioconjugates as potential therapeutic proteins, opening the possibility of extension and applicability against other different viruses.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aguilera-Rodriguez</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Instituto de Catálisis y Petroleoquímica (ICP), CSIC C/Marie Curie 2 28049 Madrid Spain josempalomo@icp.csic.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortega-Alarcon</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Instituto de Investigación Sanitaria Aragón (IIS Aragón) 50009 Zaragoza Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd) 28029 Madrid Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Biocomputation and Physics of Complex Systems, University of Zaragoza Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vazquez-Calvo</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid (UAM) 28049 Madrid Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricci</LastName><ForeName>Veronica</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Instituto de Catálisis y Petroleoquímica (ICP), CSIC C/Marie Curie 2 28049 Madrid Spain josempalomo@icp.csic.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abian</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Instituto de Investigación Sanitaria Aragón (IIS Aragón) 50009 Zaragoza Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd) 28029 Madrid Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Biocomputation and Physics of Complex Systems, University of Zaragoza Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular and Cell Biology, University of Zaragoza Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velazquez-Campoy</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto de Investigación Sanitaria Aragón (IIS Aragón) 50009 Zaragoza Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd) 28029 Madrid Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Biocomputation and Physics of Complex Systems, University of Zaragoza Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular and Cell Biology, University of Zaragoza Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcami</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid (UAM) 28049 Madrid Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palomo</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-6464-1216</Identifier><AffiliationInfo><Affiliation>Instituto de Catálisis y Petroleoquímica (ICP), CSIC C/Marie Curie 2 28049 Madrid Spain josempalomo@icp.csic.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RSC Med Chem</MedlineTA><NlmUniqueID>101759460</NlmUniqueID><ISSNLinking>2632-8682</ISSNLinking></MedlineJournalInfo><CoiStatement>There is no conflict of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>5</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39371431</ArticleId><ArticleId IdType="pmc">PMC11451904</ArticleId><ArticleId IdType="doi">10.1039/d4md00289j</ArticleId><ArticleId IdType="pii">d4md00289j</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hu B. Guo H. Zhou P. Shi Z. L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19:141–154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Anjani Kumar S. Rathi B. Poonam Recent updates on the biological efficacy of approved drugs and potent synthetic compounds against SARS-CoV-2. RSC Adv. 2023;13:3677–3687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9890797</ArticleId><ArticleId IdType="pubmed">36756584</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou N. Shuai L. Zhang L. Xie X. Tang K. Zhu Y. Yu Y. Zhang W. Tan Q. Zhong G. Wen Z. Wang C. He X. Huo H. Gao H. Xu Y. Xue J. Peng C. Zou J. Schindewolf C. Menachery V. Su W. Yuan Y. Shen Z. Zhang R. Yuan S. Yu H. Shi P.-Y. Bu Z. Huang J. Hu Q. Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro. ACS Cent. Sci. 2023;9:217–227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9885526</ArticleId><ArticleId IdType="pubmed">36844503</ArticleId></ArticleIdList></Reference><Reference><Citation>von Delft A. Hall M. D. Kwong A. D. Purcell L. A. Singh Saikatendu K. Schmitz U. Tallarico J. A. Lee A. A. Accelerating antiviral drug discovery: lessons from COVID-19. Nat. Rev. Drug Discovery. 2023;22:585–603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10176316</ArticleId><ArticleId IdType="pubmed">37173515</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian L. Qiang T. Yang X. Gao Y. Zhai X. Kang K. Du C. Lu Q. Gao H. Zhang Dezhu. Xie X. Liang C. Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection. Eur. J. Med. Chem. 2024;264:115979.</Citation><ArticleIdList><ArticleId IdType="pubmed">38048696</ArticleId></ArticleIdList></Reference><Reference><Citation>Yevsieieva L. V. Lohachova K. O. Kyrychenko A. Kovalenko S. M. Ivanov V. V. Kalugin O. N. Main and papain-like proteases as prospectiveBtargets for pharmacological treatment of coronavirus SARS-CoV-2. RSC Adv. 2023;13:35500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10698513</ArticleId><ArticleId IdType="pubmed">38077980</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y. Tang L. V. Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication. J. Proteome Res. 2021;20:49–59.</Citation><ArticleIdList><ArticleId IdType="pubmed">33347311</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand K. Palm G. J. Mesters J. R. Siddell S. G. Ziebuhr J. Hilgenfeld R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain. EMBO J. 2002;21:3213–3224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC126080</ArticleId><ArticleId IdType="pubmed">12093723</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegyi A. Ziebuhr J. Conservation of substrate specificities among coronavirus main proteases. J. Gen. Virol. 2002;83:595–599.</Citation><ArticleIdList><ArticleId IdType="pubmed">11842254</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z. Du X. Xu Y. Deng Y. Liu M. Zhao Y. Zhang B. Li X. Zhang L. Peng C. et al., Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–293.</Citation><ArticleIdList><ArticleId IdType="pubmed">32272481</ArticleId></ArticleIdList></Reference><Reference><Citation>Eastman R. T. Roth J. S. Brimacombe K. R. Simeonov A. Shen M. Patnaik S. HalL M. D. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent. Sci. 2020;6:672–683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202249</ArticleId><ArticleId IdType="pubmed">32483554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemian S. M. R. Sheida A. Taghizadieh M. Memar M. Y. Hamblin M. R. Baghi H. B. Nahand J. S. Asemi Z. Mirzaei H. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? Biomed. Pharmacother. 2023;162:114367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9899776</ArticleId><ArticleId IdType="pubmed">37018987</ArticleId></ArticleIdList></Reference><Reference><Citation>Khiali S. Khani E. Rouy S. B. Entezari-Maleki T. Comprehensive Review on Molnupiravir in COVID-19: A Novel Promising Antiviral to Combat the Pandemic. Future Microbiol. 2022;17:377–391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8961474</ArticleId><ArticleId IdType="pubmed">35199608</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismaya W. T. Rozeboom H. J. Weijn A. Mes J. J. Fusetti F. Wichers H. J. Dijkstra B. W. Crystal structure of agaricus bisporus mushroom tyrosinase: Identity of the tetramer subunits and interaction with tropolone. Biochemistry. 2011;50:5477–5486.</Citation><ArticleIdList><ArticleId IdType="pubmed">21598903</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretzler M. Bijelic A. Rompel A. Heterologous expression and characterization of functional mushroom tyrosinase (AbPPO4) Sci. Rep. 2017;7:1–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5431950</ArticleId><ArticleId IdType="pubmed">28500345</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichers H. J. Recourt K. Hendriks M. Ebbelaar C. E. M. Biancone G. Hoeberichts F. A. Mooibroek H. Soler-Rivas C. Cloning, expression and characterisation of two tyrosinase cDNAs from Agaricus bisporus. Appl. Microbiol. Biotechnol. 2003;61:336–341.</Citation><ArticleIdList><ArticleId IdType="pubmed">12743763</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichers H. J. Gerritsen Y. A. M. Chapelon C. G. J. Tyrosinase isoforms from the fruitbodies of Agaricus bisporus. Phytochemistry. 1996;43:333–337.</Citation></Reference><Reference><Citation>Lopez-Tejedor D. Clavería-Gimeno R. Velazquez-Campoy A. Abian O. Palomo J. M. In Vitro Antiviral Activity of Tyrosinase from Mushroom Agaricus bisporus against Hepatitis C Virus. Pharmaceuticals. 2021;14:759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8399381</ArticleId><ArticleId IdType="pubmed">34451856</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou N. Shuai L. Zhang L. Xie X. Tang K. Zhu Y. Yu Y. Zhang W. Tan Q. Zhong G. Wen Z. Wang C. He X. Huo H. Gao H. Xu Y. Xue J. Peng C. Zou J. Schindewolf C. Menachery V. Su W. Yuan Y. Shen Z. Zhang R. Yuan S. Yu H. Shi P. Y. Bu Z. Huang J. Hu Q. ACS Cent. Sci. 2023;9:217–227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9885526</ArticleId><ArticleId IdType="pubmed">36844503</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutureira O. Bernardes G. J. L. Advances in chemical protein modification. Chem. Rev. 2015;115:2174–2195.</Citation><ArticleIdList><ArticleId IdType="pubmed">25700113</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephanopoulos N. Francis M. B. Choosing an effective protein bioconjugation strategy. Nat. Chem. Biol. 2011;7:876–884.</Citation><ArticleIdList><ArticleId IdType="pubmed">22086289</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H. Daniel T. Buechler Y. J. Litzinger D. C. Maio Z. Putnam A. M. H. Kraynov V. S. Sim B. C. Bussell S. Javahishvili T. Kaphle S. Viramontes G. Ong M. Chu S. Becky G. C. Lieu R. Knudsen N. Castiglioni P. Norman T. C. Axelrod D. W. Hoffman A. R. Schultz P. G. DiMarchi R. D. Kimmel B. E. Optimized clinical performance of growth hormone with an expanded genetic code. Proc. Natl. Acad. Sci. U. S. A. 2011;108:9060–9065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3107295</ArticleId><ArticleId IdType="pubmed">21576502</ArticleId></ArticleIdList></Reference><Reference><Citation>Farcet J.-B. Kosma P. Determination of modification degree of polysialylated therapeutic proteins using 1H-NMR spectroscopy. Int. J. Biol. Macromol. 2021;185(31):1015–1021.</Citation><ArticleIdList><ArticleId IdType="pubmed">34197856</ArticleId></ArticleIdList></Reference><Reference><Citation>Biemans E. A. L. M. Jäkel L. de Waal R. M. W. Bea Kuiperij H. Verbeek M. M. Limitations of the hCMEC/D3 cell line as a model for Aβ clearance by the human blood-brain barrier. J. Neurosci. Res. 2017;95:1513–1522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5484315</ArticleId><ArticleId IdType="pubmed">27726164</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero O. Rivero C. W. Guisan J. M. Palomo J. M. Novel enzyme-polymer conjugates for biotechnological applications. PeerJ. 2013;2013:e27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3628993</ArticleId><ArticleId IdType="pubmed">23638362</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Tejedor D. Palomo J. M. Efficient purification of a highly active H-subunit of tyrosinase from Agaricus bisporus. Protein Expression Purif. 2018;145:64–70.</Citation><ArticleIdList><ArticleId IdType="pubmed">29326063</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedesco F. Calugi L. Lenci E. Trabocchi A. Peptidomimetic Small-Molecule Inhibitors of 3CLPro Activity and Spike–ACE2 Interaction: Toward Dual-Action Molecules against Coronavirus Infections. J. Org. Chem. 2022;87:12041–12051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9454270</ArticleId><ArticleId IdType="pubmed">36039955</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R. Gao Y. Liu H. Li H. Chen W. Ma J. Advances in research on 3C-like protease (3CLpro) inhibitors against SARS-CoV-2 since 2020. RSC Med. Chem. 2023;14:9–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9890616</ArticleId><ArticleId IdType="pubmed">36760740</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifagni D. Lenci E. De Santis A. Orsetti A. Barracchia C. G. Tedesco F. Puglielli R. B. Lucarelli F. Lauriola A. Assfalg M. Cantini F. Calderone V. Guardavaccaro D. Trabocchi A. D'Onofrio M. Ciofi-Baffoni S. Development of a GC-376 Based Peptidomimetic PROTAC as a Degrader of 3-Chymotrypsin-like Protease of SARS-CoV-2. ACS Med. Chem. Lett. 2024;15:250–257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10860180</ArticleId><ArticleId IdType="pubmed">38352832</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>